Glucose- and time-dependence of islet amyloid formation in vitro

Biochemical and Biophysical Research Communications

Volumn 354, Issue 1, 2007, Pages 234-239

  Zraika, Sakeneh ^a   Hull, Rebecca L ^a   Udayasankar, Jayalakshmi ^a   Utzschneider, Kristina M ^a   Tong, Jenny ^a   Gerchman, Fernando ^a   Kahn, Steven E ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cell; Amylin; Cell viability; Diabetes; Human islet amyloid polypeptide; Insulin secretion; Islet amyloid; Islets; Mouse model

Indexed keywords

AMYLOID; GLUCOSE; INSULIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL LOSS; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MODEL; FEMALE; IN VITRO STUDY; INSULIN RELEASE; MALE; MICROSCOPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TIME; TRANSGENIC MOUSE;

AMYLOID; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HUMANS; ISLETS OF LANGERHANS; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; TIME FACTORS;

MUS MUSCULUS;

EID: 33846265786     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.12.187     Document Type: Article

References (27)

1. Clark A., Wells C.A., Buley I.D., Cruickshank J.K., Vanhegan R.I., Matthews D.R., Cooper G.J., Holman R.R., and Turner R.C. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res. 9 (1988) 151-159
2. Westermark P. Amyloid and polypeptide hormones: what is their relationship?. Amyloid Int. J. Exp. Clin. Invest. 1 (1994) 47-60
3. Schubert D., Behl C., Lesley R., Brack A., Dargusch R., Sagara Y., and Kimura H. Amyloid peptides are toxic via a common oxidative mechanism. Proc. Natl. Acad. Sci. USA 92 (1995) 1989-1993
4. Hiddinga H.J., and Eberhardt N.L. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. Am. J. Pathol. 154 (1999) 1077-1088
5. Matveyenko A.V., and Butler P.C. Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes. ILAR J. 47 (2006) 225-233
6. Verchere C.B., D'Alessio D.A., Palmiter R.D., Weir G.C., Bonner-Weir S., Baskin D.G., and Kahn S.E. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc. Natl. Acad. Sci. USA 93 (1996) 3492-3496
7. Kahn S.E., Andrikopoulos S., Verchere C.B., Wang F., Hull R.L., and Vidal J. Oophorectomy promotes islet amyloid formation in a transgenic mouse model of Type II diabetes. Diabetologia 43 (2000) 1309-1312
8. Hoppener J.W., Oosterwijk C., Nieuwenhuis M.G., Posthuma G., Thijssen J.H., Vroom T.M., Ahren B., and Lips C.J. Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42 (1999) 427-434
9. Soeller W.C., Janson J., Hart S.E., Parker J.C., Carty M.D., Stevenson R.W., Kreutter D.K., and Butler P.C. Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. Diabetes 47 (1998) 743-750
10. de Koning E.J., Morris E.R., Hofhuis F.M., Posthuma G., Hoppener J.W., Morris J.F., Capel P.J., Clark A., and Verbeek J.S. Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. USA 91 (1994) 8467-8471
11. MacArthur D.L., de Koning E.J., Verbeek J.S., Morris J.F., and Clark A. Amyloid fibril formation is progressive and correlates with beta-cell secretion in transgenic mouse isolated islets. Diabetologia 42 (1999) 1219-1227
12. Henson M.S., Buman B.L., Jordan K., Rahrmann E.P., Hardy R.M., Johnson K.H., and O'Brien T D. An in vitro model of early islet amyloid polypeptide (IAPP) fibrillogenesis using human IAPP-transgenic mouse islets. Amyloid 13 (2006) 250-259
13. Zraika S., Dunlop M., Proietto J., and Andrikopoulos S. The hexosamine biosynthesis pathway regulates insulin secretion via protein glycosylation in mouse islets. Arch. Biochem. Biophys. 405 (2002) 275-279
14. Wang F., Hull R.L., Vidal J., Cnop M., and Kahn S.E. Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50 (2001) 2514-2520
15. Janson J., Soeller W.C., Roche P.C., Nelson R.T., Torchia A.J., Kreutter D.K., and Butler P.C. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. USA 93 (1996) 7283-7288
16. Hull R.L., Andrikopoulos S., Verchere C.B., Vidal J., Wang F., Cnop M., Prigeon R.L., and Kahn S.E. Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52 (2003) 372-379
17. Janciauskiene S., and Ahren B. Different sensitivity to the cytotoxic action of IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RINm5F cells. Biochem. Biophys. Res. Commun. 251 (1998) 888-893
18. Lorenzo A., Razzaboni B., Weir G.C., and Yankner B.A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368 (1994) 756-760
19. Westermark G., Arora M.B., Fox N., Carroll R., Chan S.J., Westermark P., and Steiner D.F. Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. Mol. Med. 1 (1995) 542-553
20. Westermark G.T., Gebre-Medhin S., Steiner D.F., and Westermark P. Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol. Med. 6 (2000) 998-1007
21. Hull R.L., Westermark G.T., Westermark P., and Kahn S.E. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 3629-3643
22. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., and Butler P.C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
23. Westermark P., and Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15 (1978) 417-421
24. Lee H.C., Bonner-Weir S., Weir G.C., and Leahy J.L. Compensatory adaption to partial pancreatectomy in the rat. Endocrinology 124 (1989) 1571-1575
25. Ward W.K., Wallum B.J., Beard J.C., Taborsky G.J.J., and Porte D J. Reduction of glycemia potentiation: sensitive indicator of B-cell loss in partially pancreatectomized dogs. Diabetes 37 (1988) 733-739
26. Zhang S., Liu J., Dragunow M., and Cooper G.J. Fibrillogenic amylin evokes islet beta-cell apoptosis through linked activation of a caspase cascade and JNK1. J. Biol. Chem. 278 (2003) 52810-52819
27. Hull R.L., Shen Z.P., Watts M.R., Kodama K., Carr D.B., Utzschneider K.M., Zraika S., Wang F., and Kahn S.E. Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 54 (2005) 2235-2244